SPDL1 and neoplasm: High levels of sPD-L1, in patients undergoing treatment with Nivolumab, was correlated with a decrease in median PFS [61].Decrease in plasma levels of sPD-L1 was significantly associated with tumor regression in patients treated with ICIs [59].